Nov 3
RVTY · Revvity, Inc.
$158.36
+7.53 (+4.99%)
At close · Nov 6
Return incl. dividend (before tax)
Market Cap
$17.32B
Shares
111.59M
Volume · Nov 6
687.13K
Avg daily vol (3M)
1.89M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$150.83
Open$157.67
Day$150.37–158.78
52W close$82.26–165.78
Avg vol 30d2.0M
Short int6.4M · 5.7% of shares · 3.6d
Short vol47%
Last earningsNov 3, 2026
DataJan 2020–Nov 2026
Filing10-Q · Aug 11
Up next
Feb 3, 2027
Est · unconfirmed
· in 13 wks
Latest documents
2026
Nov 3
Current report
8-K
Financial results, Other events
Revvity reported third-quarter revenue of $729 million and EPS from continuing operations of $0.56, raised 2026 pro forma guidance to $2.86 billion revenue and $5.40-$5.45 adjusted EPS, and agreed to sell its China immunodiagnostics assets for up to $200 million.
Sep 15
Sep 14
Sep 9
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.91B
Trailing 12 months
Net income (TTM)
$237.55M
Trailing 12 months
Revenue growth YoY
+1.3%
Year over year
Operating margin
12.3%
Trailing 12 months
P / E (TTM)
76.3
Trailing earnings · reciprocal yield 1.3%
FCF yield
3.2%
TTM · current market cap
Return on invested capital
3.5%
Trailing 12 months
Net cash
−$2.18B
Latest balance sheet
Dividend yield
0.2%
Trailing 12 months
Shares change YoY
-5.0%
Year over year · fewer shares
Price change (1Y)
+73.9%
Trailing year
Short interest
5.7%
Latest settlement · 3.6 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Revvity beat Q2 expectations and raised full-year guidance, now expecting 4-5% pro forma organic growth (up from 3-4%) and adjusted EPS of $5.30-$5.40 (up $0.10), driven by accelerating AI-related demand and strong Diagnostics, while entering a definitive agreement to divest its China Immunodiagnostics business by end of 2027.
Bullish
- + Raised full-year pro forma organic growth outlook to 4-5% from prior 3-4%.
- + Raised full-year pro forma adjusted EPS outlook to $5.30-$5.40, up $0.10 from prior guidance.
- + High-content screening (Opera Phoenix OptIQ) saw double-digit order growth with backlog outpacing near-term production capacity, signaling strong AI-driven demand.
- + Q2 pro forma adjusted operating margin of 29.3% exceeded the 27% guidance even excluding $16M of tariff refunds, with 117% cash flow conversion of adjusted net income.
Bearish
- − Pharma and biotech customer sales declined mid-single digits in Q2 (excluding software, only low single-digit growth) due to difficult prior-year comps.
- − Reproductive health is expected to decelerate sharply to low-to-mid single digit organic growth in H2 from mid-teens in H1, due to Genomics England comps and heavier H1 instrument placements.
- − Management reinvested roughly half of the Q2 tariff refund benefit, muting full-year EPS upside relative to gross tariff benefit.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 28.2 · fear
Equity put/call 0.89
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+3%
above
RSI (14)
47
neutral
MACD trend
Negative
52-week position
82%
mid-range
Momentum
relative strength
1-month return
−1%
trailing
6-month return
+61%
trailing
YTD return
+56%
this year
Relative strength
+61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $147 › 200d $113 — 50d above 200d
Institutional flow
Accumulating
269 of 548 funds reported for Sep 30 · net +474.5K sh shares · +48 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.73% of shares out · ▲ +1.4% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
548 holders — near 3-yr high, broad support
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
−13%
Y/Y
Gross margin
60%
contracting
EPS growth
−6%
Y/Y
Free cash flow
$509.4M
Valuation
P/E 74.3
rich
Buyback
$792.7M
remaining
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
5.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 4, 2026
this year
Pro forma organic growth
Non-GAAP
4% – 5%
Adjusted operating margin
Non-GAAP
28.7%
2026 full year
Pro forma total revenue
Non-GAAP
Raised
$2.83B – $2.86B
May 5, 2026
$2.81B – $2.84B
changed to
Aug 4, 2026
$2.83B – $2.86B
Pro forma adjusted operating margin
Non-GAAP
28.7%
Net interest and other expense
$90M
Adjusted tax rate
Non-GAAP
Maintained
18%
May 5, 2026
18%
changed to
Aug 4, 2026
18%
Diluted average share count
$112000000.00
this year / 2026 full year
Adjusted earnings per share
Non-GAAP
Raised
$5.30 – $5.40
May 5, 2026
$5.20 – $5.30
changed to
Aug 4, 2026
$5.30 – $5.40
Previous outlook
earlier release
· from the Earnings Call filed May 5, 2026
Still-open targets the latest release did not restate under the same label.
Total company organic growth
· 2026
3% – 4%
Adjusted operating margins
· 2026
28.4%
Organic growth
· 2026
3% – 4%
Pro forma organic growth
· 2026
3% – 4%
Pro forma adjusted operating margins
· 2026
28.4%
Net interest expense and other
· 2026
$90M
Operating margin
· 2026 full year
28.4%
Prior guidance
period ended
· from the Earnings Call filed May 5, 2026
Pro forma total revenue
· second quarter
$699M – $707M
Pro forma adjusted operating margins
· second quarter
27%
Guided vs delivered
· last 8 settled
Full year revenue
full year 2025
guided $2.83B – $2.88B
$2.86B
In line
Revenue
full year 2024
guided $2.77B – $2.79B
$2.76B
Miss −0.9%
Total revenue
full year 2023
guided $2.9B – $2.94B
$2.75B
Miss −5.8%
Total revenue from continuing operations
fourth quarter of 2022
guided $730M
$741.21M
Beat +1.5%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
47
Neutral
MACD trend
Negative
Bearish
52-week position
82%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $147 › 200d $113 — 50d above 200d
Institutional flow
Accumulating
269 of 548 funds reported for Sep 30 · net +474.5K sh shares · +48 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.73% of shares out · ▲ +1.4% MoM · 3.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
548 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $82
Now $151 · 82%
Range high $166
vs 200-day avg +34%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Effective tax rate from continuing operations | 15.8% | the three months ended July 5, 2026 filing | — |
| Research and development expenses as a percentage of revenue | 6.7% | the three months ended July 5, 2026 filing | — |
| Shares repurchased under Repurchase Program | 93,303 | the three months ended July 5, 2026 filing | — |
| Adjusted EPS from continuing operations non-GAAP | $2.47 | Six Months Ended July 5, 2026 | — |
| Adjusted operating income non-GAAP | 378.86M | Six Months Ended July 5, 2026 | — |
| Adjusted operating income (Diagnostics) non-GAAP | 113M | Second quarter 2026 | — |
| Adjusted operating income (Life Sciences) non-GAAP | 112M | Second quarter 2026 | — |
| Adjusted operating margin (OP%) non-GAAP | 26.3% | Six Months Ended July 5, 2026 | — |
| Adjusted operating profit margin non-GAAP | 28.9% | the second quarter ended July 5, 2026 | — |
| Adjusted operating profit margin (Diagnostics) non-GAAP | 30.4% | Second quarter 2026 | — |
| Adjusted operating profit margin (Life Sciences) non-GAAP | 31.1% | Second quarter 2026 | — |
| Pro forma adjusted operating income non-GAAP | 209M | the second quarter ended July 5, 2026 | — |
| Pro forma adjusted operating profit margin non-GAAP | 29.3% | the second quarter ended July 5, 2026 | — |
| Pro forma organic revenue growth non-GAAP | 3% | the second quarter ended July 5, 2026 | — |
| Pro forma organic revenue growth (Diagnostics) non-GAAP | 11% | Second quarter 2026 | — |
| Pro forma organic revenue growth from continuing operations non-GAAP | 4% | Six Months Ended July 5, 2026 | — |
| Pro forma organic revenue growth from continuing operations (Diagnostics) non-GAAP | 10% | Six Months Ended July 5, 2026 | — |
| Pro forma organic revenue growth from continuing operations (Life Sciences) non-GAAP | 0% | Six Months Ended July 5, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RVTY
this stock
Revvity, Inc.
|
$17.32B | +55.9% | -13.5% | 74.3 | 5.7% |
|
TMO
Thermo Fisher Scientific Inc.
|
$250.82B | +16.8% | +14.5% | 35.7 | 1.3% |
|
DHR
Danaher Corp
|
$159.24B | -1.1% | +8.5% | 37.0 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$52.84B | -0.9% | +10.4% | 45.2 | 2.4% |
|
A
Agilent Technologies, Inc.
|
$48.43B | +26.2% | +6.4% | 33.8 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Nov 3, 2026
- This year
- 17
Revvity reported third-quarter revenue of $729 million and EPS from continuing operations of $0.56, raised 2026 pro forma guidance to $2.86 billion revenue and $5.40-$5.45 adjusted EPS, and agreed to sell its China immunodiagnostics assets for up to $200 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RVTY | -9.0% | -0.9% | +60.5% | -3.9% | +55.9% |
| SPY | -4.7% | -5.3% | -0.8% | -3.0% | +7.5% |
| vs SPY | -4.3% | +4.4% | +61.3% | -0.9% | +48.4% |
Capital returns
Latest dividend
$0.07
/ share · ex Oct 23, 2026
Declared · upcoming
$0.07
/ share · ex Jan 22, 2027
Paid (TTM)
$0.28
/ share · 4 payouts
Dividend yield (TTM, derived)
0.19%
Buyback program
· as of Jul 5, 2026
Authorized
$1.00B
Spent (derived)
$207.30M
Remaining
$792.70M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
31791
CUSIP
714046109
13F (30d)
288 filings
250 filers
Visit website
Investor relations